RA0144

antibody from Oursmab

Targeting: CLDN18 SFTPJ

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0144

Provider

Oursmab

Product name

Zolbetuximab (Biosimilar Reference Antibody) (CLDN18)

Antibody type

Monoclonal

Description

Zolbetuximab (IMAB-362) is a chimeric monoclonal antibody that targets Claudin 18.2 (CLDN18.2), a tight junction protein isoform. It is approved and indicated for the treatment of CLDN18.2-positive, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. As an IgG1 antibody, it induces tumor cell death primarily through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Zolbetuximab (Biosimilar Reference Antibody) (CLDN18)-RA0144-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.